IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Fiscal Year End 2024 on July 25th, 2024

Rhea-AI Summary

ImmunoPrecise Antibodies (IPA), an AI-driven biotherapeutic research and technology company, has announced it will release its financial results and business highlights for the fourth quarter and fiscal year 2024 on July 25th, 2024. The company will host an earnings conference call via webcast at 10:30 AM Eastern Time on the same day.

Investors can access the live audio webcast through a link on IPA's Investor Relations website. A replay will be available after the call. Participants can join the conference call using provided toll-free and international dial-in numbers, using the Conference ID 9236374 or Conference Name.

The Company to host an earnings conference call via webcast

VICTORIA, British Columbia--(BUSINESS WIRE)-- IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, will announce its full year fiscal 2024 financial results and business highlights on Thursday, July 25, 2024, and will hold an earnings call at 10:30 am Eastern Time the same day.

A live audio webcast of the earnings conference may be accessed through a link that will be posted on IPA’s Investor Relations website at ir.ipatherapeutics.com. A replay will be archived and available for replay following the conference call.

Conference Call:
Event Title: ImmunoPrecise Reports Financial Results and Recent Business Highlights for Full Fiscal Year 2024
Event Date: July 25th, 2024
Time: 10:30 AM (GMT-04:00) Eastern Time (US and Canada)

***Participant Dial-In Details***
Participants call one of the allocated dial-in numbers (below) and advise the Operator of either the Conference ID 9236374 or Conference Name.

North America Toll-Free: (888) 550-5658
North America Toll: (646) 960-0289
International Toll: +1(646) 960-0289

***Webcast Details ***
Attendee URL:
https://events.q4inc.com/attendee/388047633

About ImmunoPrecise Antibodies Ltd.

The IPA Family is a biotherapeutic research and technology group that leverages systems biology, multi-omics modelling and complex artificial intelligence systems to support its proprietary technologies in bioplatform-based antibody discovery. Services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics against the most challenging targets. ImmunoPrecise Antibodies Ltd. has several subsidiaries in North America and Europe including entities such as Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies (Europe) B.V. (collectively, the “IPA Family”). For further information, visit www.ipatherapeutics.com.

Forward-Looking Statement:

This news release contains forward-looking statements within the meaning of applicable United States securities laws and Canadian securities laws. Forward-looking statements are often identified by the use of words such as “potential”, “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. In respect of the forward-looking information contained herein, IPA has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time.

Forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. Actual results could differ materially from those currently anticipated due to a number of factors and risks, as discussed in the Company’s Annual Information Form dated July 10, 2023 (which may be viewed on the Company’s profile at www.sedar.com), and the Company’s Form 40-F, dated July 10, 2023 (which may be viewed on the Company’s profile at www.sec.gov). Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. Accordingly, readers should not place undue reliance on forward-looking information contained in this news release. The forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. The Company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240715388760/en/

Investor contact: investors@ipatherapeutics.com

Source: ImmunoPrecise Antibodies Ltd.

FAQ

When will ImmunoPrecise Antibodies (IPA) report its Q4 and FY 2024 financial results?

ImmunoPrecise Antibodies (IPA) will report its Q4 and fiscal year 2024 financial results on July 25th, 2024.

What time is IPA's earnings conference call for Q4 and FY 2024 results?

IPA's earnings conference call for Q4 and FY 2024 results is scheduled for 10:30 AM Eastern Time on July 25th, 2024.

How can investors access IPA's Q4 and FY 2024 earnings call?

Investors can access IPA's Q4 and FY 2024 earnings call via a live audio webcast through a link on IPA's Investor Relations website or by dialing in using the provided toll-free and international numbers.

What is the Conference ID for IPA's Q4 and FY 2024 earnings call?

The Conference ID for IPA's Q4 and FY 2024 earnings call is 9236374.